Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals (KALV)
NASDAQ:KALV
KALV Analyst Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KALV Stock 12 Month Forecast
Average Price Target
$31.67
▲(134.59% Upside)
| Highest Price Target$40.00 | Average Price Target$31.67 | Lowest Price Target$20.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$27
Buy
100.00%
Upside
Reiterated
09/15/25
Promising Launch of Ekterly Boosts KalVista Pharmaceuticals' Market PotentialValuation and Risks. With the successful FDA approval and launch of Ekterly (sebetralstat), we reiterate our price target of $27 and our Buy rating. Our $27 price target is based on an equally weighted composite of: (a) $28.51/ share, as a 25x multiple of taxed and diluted 2035E EPS of $3.16 discounted back to and (b) an NPV discounted cash flow of $25.88/share with a discount rate of 12% and growth rate of 2%. These assumptions are in line with the expected P/E multiple and discount rates of a developmental stage biopharmaceutical company.
Leerink Partners
$20
Buy
48.15%
Upside
Reiterated
09/15/25
Citizens JMP
$27→$28
Buy
107.41%
Upside
Reiterated
09/12/25
Needham
$28
Buy
107.41%
Upside
Reiterated
09/12/25
Strong Initial Sales and Medical Endorsement Drive Buy Rating for KalVista Pharmaceuticals' EkterlyWe expect most of these initial patient starts to become paid Rxs, initially via medical exemptions, and eventually thru formulary coverage. Overall, Ekterly is off to a solid initial launch, and should better reflect solid initial demand when the co. reports 3Q25 in Nov. We updated our model (see below) to reflect the co's planned transition to a 12/31 calendar yr-end starting in 3Q25. We maintain our Buy rating and $28PT.
JonesTrading
$37
Buy
174.07%
Upside
Reiterated
09/11/25
TD Cowen
$30
Buy
122.22%
Upside
Reiterated
09/11/25
Promising Outlook for KalVista Pharmaceuticals: Buy Rating Justified by Strong Launch Metrics and Strategic Initiatives for EkterlyWe are encouraged by the impressive clinician activation and steady access/reimbursement progress. KOLs believe there will be high/growing patient demand given Ekterly's differentiated profile as an oral agent with SQ-like efficacy. We expect $750MM+ in peak sales. Buy.
Bank of America Securities
$37→$36
Buy
166.67%
Upside
Reiterated
09/11/25
Jefferies
$32→$40
Buy
196.30%
Upside
Reiterated
07/08/25
Cantor Fitzgerald
―
Buy
―
Reiterated
03/26/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$27
Buy
100.00%
Upside
Reiterated
09/15/25
Promising Launch of Ekterly Boosts KalVista Pharmaceuticals' Market PotentialValuation and Risks. With the successful FDA approval and launch of Ekterly (sebetralstat), we reiterate our price target of $27 and our Buy rating. Our $27 price target is based on an equally weighted composite of: (a) $28.51/ share, as a 25x multiple of taxed and diluted 2035E EPS of $3.16 discounted back to and (b) an NPV discounted cash flow of $25.88/share with a discount rate of 12% and growth rate of 2%. These assumptions are in line with the expected P/E multiple and discount rates of a developmental stage biopharmaceutical company.
Leerink Partners
$20
Buy
48.15%
Upside
Reiterated
09/15/25
Citizens JMP
$27→$28
Buy
107.41%
Upside
Reiterated
09/12/25
Needham
$28
Buy
107.41%
Upside
Reiterated
09/12/25
Strong Initial Sales and Medical Endorsement Drive Buy Rating for KalVista Pharmaceuticals' EkterlyWe expect most of these initial patient starts to become paid Rxs, initially via medical exemptions, and eventually thru formulary coverage. Overall, Ekterly is off to a solid initial launch, and should better reflect solid initial demand when the co. reports 3Q25 in Nov. We updated our model (see below) to reflect the co's planned transition to a 12/31 calendar yr-end starting in 3Q25. We maintain our Buy rating and $28PT.
JonesTrading
$37
Buy
174.07%
Upside
Reiterated
09/11/25
TD Cowen
$30
Buy
122.22%
Upside
Reiterated
09/11/25
Promising Outlook for KalVista Pharmaceuticals: Buy Rating Justified by Strong Launch Metrics and Strategic Initiatives for EkterlyWe are encouraged by the impressive clinician activation and steady access/reimbursement progress. KOLs believe there will be high/growing patient demand given Ekterly's differentiated profile as an oral agent with SQ-like efficacy. We expect $750MM+ in peak sales. Buy.
Bank of America Securities
$37→$36
Buy
166.67%
Upside
Reiterated
09/11/25
Jefferies
$32→$40
Buy
196.30%
Upside
Reiterated
07/08/25
Cantor Fitzgerald
―
Buy
―
Reiterated
03/26/25
Best Analysts Covering KalVista Pharmaceuticals
1 Month
xxx
Success Rate
10/21 ratings generated profit
Average Return
+2.38%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.62% of your transactions generating a profit, with an average return of +2.38% per trade.
3 Months
xxx
Success Rate
12/21 ratings generated profit
Average Return
+12.59%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +12.59% per trade.
1 Year
Success Rate
18/21 ratings generated profit
Average Return
+27.64%
reiterated a buy rating 6 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +27.64% per trade.
2 Years
xxx
Success Rate
12/12 ratings generated profit
Average Return
+34.57%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +34.57% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KALV Analyst Recommendation Trends
Rating
Mar 25
Apr 25
Jun 25
Jul 25
Sep 25
Strong Buy
19
23
27
26
27
Buy
3
4
9
7
7
Hold
3
3
3
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
30
39
34
34
Each month's total comprises the sum of three months' worth of ratings.
KALV Financial Forecast
KALV Stock Forecast FAQ
What is KALV’s average 12-month price target, according to analysts?
Based on analyst ratings, KalVista Pharmaceuticals’s 12-month average price target is 31.67.
What is KALV’s upside potential, based on the analysts’ average price target?
KalVista Pharmaceuticals has 134.59% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KALV a Buy, Sell or Hold?
KalVista Pharmaceuticals has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
What is KalVista Pharmaceuticals’s price target?
The average price target for KalVista Pharmaceuticals is 31.67. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $20.00. The average price target represents 134.59% Increase from the current price of $13.5.
The highest analyst price target is $40.00 ,the lowest forecast is $20.00. The average price target represents 134.59% Increase from the current price of $13.5.
What do analysts say about KalVista Pharmaceuticals?
KalVista Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of KALV?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.